肝细胞癌诊断后使用他汀类药物与死亡率降低相关
该回顾性分析纳入2002至2016年退伍军人事务部中央癌症登记处15422例肝细胞癌患者,采用时间依赖Cox回归计算调整风险比。诊断后他汀使用与癌症特异性死亡风险降低(调整HR 0.85,95%CI 0.77-0.93)及全因死亡风险降低(HR 0.89,95%CI 0.83-0.95)相关,高剂量与低剂量使用均一致,且不受诊断前他汀使用或表现/治疗相关因素影响。
要点
- 诊断后他汀使用与肝细胞癌患者癌症特异性死亡风险降低相关(调整HR 0.85)。
- 诊断后他汀使用与全因死亡风险降低相关(HR 0.89)。
- 高剂量与低剂量他汀的负相关程度一致,且在不同滞后时间段(0至12个月)均持续存在。
核心结论
- 在肝细胞癌退伍军人回顾性分析中,诊断后使用他汀(高或低剂量)与死亡率降低相关。
研究设计与样本
- 回顾性分析,数据来自退伍军人事务部中央癌症登记处,纳入2002年至2016年诊断的15422例肝细胞癌患者。
- 采用时间依赖Cox回归模型计算调整风险比(HR)及95%CI,使用时变暴露避免 immortal time bias,并设3个月滞后(从癌症诊断后3个月开始随访)以减少反向因果。
- 进行敏感性分析,改变癌症诊断日期与随访开始之间的滞后时长。
主要发现
- 诊断后他汀使用记录于14.9%的肝细胞癌患者。
- 诊断后他汀使用与癌症特异性死亡风险降低相关(调整HR 0.85;95%CI 0.77-0.93)。
- 诊断后他汀使用与全因死亡风险降低相关(HR 0.89;95%CI 0.83-0.95)。
- 高剂量或低剂量他汀使用者的负相关程度一致,且负相关在0至12个月滞后期间均持续存在。
- 未发现诊断前他汀使用或表现/治疗相关因素对效应有修饰作用,诊断前他汀使用无独立关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Statin use is associated with a lower risk of developing hepatocellular carcinoma (HCC). However, it is unclear whether postdiagnosis statin use is associated with a reduced risk of death in patients with HCC. METHODS: We performed a retrospective analysis of data from 15,422 patients with HCC in the Veterans Administration Central Cancer Registry, diagnosed from 2002 through 2016. We identified statin prescriptions that were filled before and after the cancer diagnosis and used time-dependent Cox regression models to calculate adjusted hazard ratios (HRs) and 95% CIs for risk of death. We used a time-varying exposure to avoid immortal time bias, and a 3-month lag (following up patients from 3 months after the cancer diagnosis) to reduce reverse causation. A sensitivity analysis was conducted varying the lag duration between date of cancer diagnosis and start of follow-up evaluation. RESULTS: Statin use after diagnosis was recorded for 14.9% of patients with HCC. We found that postdiagnosis statin use was associated with a decreased risk of cancer-specific death (adjusted HR, 0.85; 95% CI, 0.77-0.93) and all-cause mortality (HR, 0.89; 95% CI, 0.83-0.95). The magnitudes of these inverse associations were consistent for patients who used high or low doses of statins, and the inverse associations remained across a range of lag periods (from 0 months to 12 months after HCC diagnosis). We found no evidence for effect modification by prediagnosis statin use, or by presentation- or treatment-related factors, and no independent association with prediagnosis statin use. CONCLUSIONS: In a retrospective analysis of data from veterans with HCC, use of statins (high or low doses) after a diagnosis of HCC was associated with reduced mortality.
引用
- Thrift AP, Natarajan Y, Liu Y, et al. Statin Use After Diagnosis of Hepatocellular Carcinoma Is Associated With Decreased Mortality. Clin Gastroenterol Hepatol. 2019. PMID: 30625400. doi:10.1016/j.cgh.2018.12.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。